What is the appropriate cefepime dose for an adult with chronic kidney disease stage 3 (estimated GFR 30–59 mL/min)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Cefepime Dosing for CKD Stage 3

For adults with CKD stage 3 (eGFR 30-59 mL/min), adjust cefepime to 1-2 g every 24 hours depending on infection severity, or 2 g every 12 hours for severe infections requiring higher doses.

Dosing Algorithm by Creatinine Clearance

The FDA-approved dosing adjustments for cefepime in renal impairment are based on creatinine clearance (CrCl), which corresponds to CKD stage 3 1:

For CrCl 30-60 mL/min (CKD 3):

  • Mild-moderate UTI: 500 mg every 24 hours
  • Standard infections (pneumonia, skin/soft tissue): 1 g every 24 hours
  • Severe infections (complicated UTI, severe pneumonia): 2 g every 24 hours
  • Febrile neutropenia or Pseudomonas coverage: 2 g every 12 hours

The initial loading dose should match the normal renal function dose before transitioning to the adjusted maintenance schedule 1.

Key Clinical Considerations

Renal function estimation matters: Use the Cockcroft-Gault equation to calculate CrCl for dosing decisions, as this is what the FDA label and clinical trials used 1. The newer CKD-EPI equations may overestimate GFR by 4-5 mL/min/1.73m² compared to older equations, potentially leading to overdosing 2.

Neurotoxicity risk increases significantly in CKD: Cefepime accumulation causes encephalopathy, confusion, myoclonus, and seizures, particularly when trough concentrations exceed 20-35 mg/L 3, 4, 5. This occurs in approximately 10% of patients with renal impairment despite dose adjustment 4. The risk is highest with:

  • CrCl <30 mL/min
  • Pre-existing neurological conditions
  • Failure to adjust doses appropriately

Monitor for hidden neurotoxicity: Non-convulsive symptoms (confusion, muscle jerks) may not be immediately attributed to cefepime 4. If unexplained neurological changes occur, consider therapeutic drug monitoring (TDM) and temporarily discontinue cefepime 3, 5.

Pharmacokinetic Rationale

Cefepime elimination half-life increases from 2 hours in normal renal function to 13.5 hours in patients requiring hemodialysis 6. Total body clearance decreases proportionally with creatinine clearance 6. In CKD stage 3, the clearance reduction necessitates either dose reduction or interval extension to prevent accumulation 7, 6.

Recent population PK studies in critically ill patients suggest that for CKD 3 with severe infections, extended infusion strategies (e.g., 2 g over 4 hours every 12 hours) may optimize the pharmacodynamic target (time above MIC) while minimizing neurotoxicity risk 7, 5. However, standard 30-minute infusions remain the FDA-approved method 1.

Practical Pitfalls to Avoid

  1. Don't use normal dosing in CKD 3: Even mild renal impairment (CrCl 50 mL/min) requires adjustment to prevent accumulation 1, 6

  2. Don't rely solely on serum creatinine: Calculate actual CrCl using Cockcroft-Gault with current weight and age 1

  3. Don't ignore dynamic renal function: Renal function can fluctuate in acute illness; reassess CrCl if clinical status changes 7, 5

  4. Don't overlook the lower threshold: If CrCl drops below 30 mL/min (CKD 4), further dose reduction to 500 mg-1 g every 24 hours is required 1

Related Questions

What is the appropriate cefepime dosing regimen for an adult patient with a creatinine clearance of 50 mL/min?
In an adult with normal renal function, when should cefepime be preferred over ceftriaxone, and what are the appropriate dosing regimens and renal adjustments for each drug?
What are the recommended cefepime dosing regimens for adults (including adjustments for renal impairment) and children, and the appropriate treatment duration?
What cefepime dosing regimen should be used for an 82-year-old, 83-kg patient with a creatinine clearance of 69 mL/min who has sepsis?
What are the indications, dosing regimen, renal dose adjustments, treatment duration, and monitoring considerations for cefepime in adults?
Can administration of contrast during endoscopic retrograde cholangiopancreatography (ERCP) in a patient with cholangitis worsen the infection when a complete sphincterotomy has been performed, the common bile duct (CBD) has been cleared, and a stent has been placed?
What are the surgical options for basal cell carcinoma on the face?
What is the recommended acyclovir dosage for acute Bell's palsy?
What preventive health maintenance evaluations, screenings, laboratory tests, and immunizations are recommended for a routine, non‑Medicare annual visit in an adult aged 18‑64?
Is there a recommended routine annual wellness visit for adults aged 80 years and older?
Is it normal for bilirubin to rise slightly, prothrombin time (PT) to increase markedly, and white blood cell count to rise in a patient who feels better with no abdominal pain or fever?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.